PO.TB03.06 · 肿瘤生物学
致癌性 ASPP2 kappa 在肿瘤微环境中发挥调控作用并在 TNBC 模型中促进转移
Oncogenic ASPP2 kappa exerts a regulatory role within the tumor microenvironment and promotes metastasis in TNBC models
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
乳腺癌迄今仍是女性最常见的癌症。虽然局限期的治愈率相对良好,但在远处转移期,肿瘤相关死亡率急剧上升。肿瘤微环境的组成在其中起着决定性作用。转移是一个复杂的多步骤过程,涉及大量细胞内转化步骤以及肿瘤细胞与周围环境的相互作用。这些过程背后的机制仅被部分了解。我们有证据表明,ASPP2 κ——一种新型的、p53 相关抑癌基因 ASPP2 的致癌异构体——参与了这一过程。ASPP2 κ 在乳腺癌中高表达,其特征为丢失了 p53 结合位点以及 BCL-2 和 NFκB 结合位点,从而损害了控制细胞命运的主要通路。我们已证明,ASPP2 κ 促进更具侵袭性的肿瘤生物学特性并缩短患者生存期。我们现在表明,ASPP2 κ 在肿瘤微环境中发挥促肿瘤作用,促进新生血管生成和早期转移。为在组织背景下研究 ASPP2 κ 的作用,我们建立了 TNBC ASPP2 κ 敲低(KD)NOD/SCID 模型以及免疫功能健全的 BALB/C 原位 ASPP2κ 敲入(knock-in)小鼠模型,采用人源 TNBC MDA-MB-231 和鼠源 4T1 细胞系。对 ASPP2 κ KD 和 KI 的原发灶及转移灶以及各自的对照进行外植并在转录和翻译水平上进行分析。在 TNBC 细胞模型上进行了蛋白质组芯片和全转录组 RNA 测序。结果通过 qPCR、WB、FACS 和 ELISA 检测得以确认。所有开展的分析均证实 ASPP2 κ 在血管生成和早期转移中起驱动作用,并在微环境中发挥促肿瘤作用。对全转录组 RNA 测序数据的综合分析确定了聚集在 GO 术语“血管生成”“EMT”和“免疫应答”中的基因存在显著的差异表达模式(GO:0001525 血管生成中的 149/200 个基因、与 GO:0001837 EMT 相关的 33/43 个基因以及与 GO:0006955 免疫应答相关的 134/194 个基因)。依据 ASPP2 κ 表达情况,详细研究了参与转移、血管生成和促炎信号传导的通路。ELISA 读数证实了促血管生成生长因子(如 VEGF、血管生成素或 PDGF)的分泌依赖于 ASPP2 κ 表达(KD 细胞:VEGF 247.2 ± 97.8 pg/mL,对照为 535.9 ± 60.8 pg/mL)。TNBC 类肿瘤(tumoroid)模型证实了在 ASPP2 κ 减弱的模型中侵袭性生长受到抑制。血管化的差异经免疫组织化学和共聚焦显微镜得以确认。
我们在此证明,ASPP2 κ 对转移和肿瘤微环境的关键标志发挥调控作用,促进肿瘤进展和转移。未来对 ASPP2 κ 进行治疗性抑制可能提供一种全新的抗转移方法。
查看英文原文 English abstract
Breast Cancer is the most common cancer in woman to date. While cure rates in localized stages are relatively good, tumor-associated death rates increase dramatically in the distant metastatic stage. Composition of the tumor microenvironment plays a decisive role therein. Metastasis is a complex, multistep process involving a multitude of intracellular steps of transformation, as well as interactions of tumor cells with the surrounding environment. The mechanisms underlying these processes are only partially understood. We have evidence that ASPP2 κ , a novel, oncogenic isoform of the p53-related tumor suppressor ASPP2, is involved in this process. ASPP2 κ is highly expressed in breast cancer and characterized by loss of the p53- as well as BCL-2 and NFκB-binding sites, impairing major pathways controlling cellular fate. We have demonstrated, that ASPP2 κ promotes a more aggressive tumor biology and shorter patient survival. We now show that ASPP2 k exerts a pro-tumorigenic role within the tumor microenvironment, facilitating neo-angiogenesis and early metastasis. To study the role of ASPP2 κ in a tissue context, we established a TNBC ASPP2 κ knock-down (KD) NOD/SCID as well as an immunocompetent BALB/C orthotopic ASPP2k knock-in mouse model, employing the human TNBC MDA-MB-231 and the murine 4T1 cell lines. ASPP2 k KD and KI primary and metastatic lesions, as well as the respective controls, were explanted and analyzed on the transcriptional and translational level. Proteome arrays and bulk RNA sequencing was performed on TNBC cell models. Results were confirmed by qPCR, WB, FACS and ELISA assays. All conducted analyses confirme a driving role of ASPP2 k in angiogenesis and early metastasis as well as a tumor promoting role in the microenvironment. Comprehensive analyses of our bulk RNA sequencing data identified significant differential expression patterns of genes clustered within the GO terms “angiogenesis”, “EMT” and “immune response” (149/200 genes within GO:0001525 angiogenesis, 33/43 genes associated with GO:0001837 EMT and 134/194 genes linked to the GO:0006955 Immune Response). Pathways involved in metastasis, angiogenesis and pro-inflammatory signaling were studied in detail in dependency of ASPP2 κ expression. ELISA readouts confirmed secretion of pro-angiogenic growth factors (eg. VEGF, Angiogenin or PDGF) in dependency of ASPP2 κ expression (KD cells: VEGF 247.2 ± 97.8 pg/mL vs. 535.9 ± 60.8 pg/mL in controls). TNBC tumoroid models confirme inhibition of invasive growth in ASPP2 κ attenuated models. Differences in vascularization were confirmed by immunohistochemistry and confocal microscopy.
We here demonstrate, that ASPP2 κ exerts a regulatory role on key hallmarks of metastasis and the tumor microenvironment, promoting tumor progression and metastasis. Therapeutic inhibition of ASPP2 κ might provide a completely new approach to combat metastasis in the future.
利益披露 Disclosure
C. Wincek, None..
A. Ruiba, None..
W. Liu, None..
S. Kembu Chettiar Ravichandran, None..
M. M. Schittenhelm, None..
K. M. Kampa-Schittenhelm, None.